skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

On 25 April 2013, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) stunned Pfizer by issuing a negative opinion of Xeljanz (tofacitinib), an oral small molecule inhibitor of Janus kinase (JAK), in the treatment of moderate to severe rheumatoid arthritis (RA).

Highlights in this whitepaper include:

  • Safety profile of Xeljan
  • Predictions on the outcome for Xeljanz in the EU
  • The most likely outcome for Xeljanz in EU

The Future of Xeljanz for Rheumatoid Arthritis in the EU

Datamonitor Healthcare conducted an online survey in order to gauge the opinions of key leaders in the eld of rheumatology regarding the eect of the CHMP’s announcement on the expected timeline for Xeljanz’s approval in the EU

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: